In recent years, some studies have reported the value of SHOX2 and RASSF1A gene methylation in the clinicopathological diagnosis of lung cancer [6], while there are not many studies on the expression of SHOX2, RASSF1A, and PTGER4 and their methylation under different clinicopathological features in lung cancer patients. This evidence concerns the gene PTGER4 and lung carcinoma.